OKYO Pharma (OKYO)
Develops urcosimod eye drops for neuropathic corneal pain and anterior-segment eye diseases.
$1.34
vs last close−0.01 (−1.11%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 71.33% | 27.37M ADS | |
|---|---|---|---|
| 10 holders · as of Aug 7, 2026 | |||
| Other | 28.67% | 11.00M ADS | |
| remainder | |||
38.37M ADS as of Sep 14, 2026 · holders as of their latest filing
The share count is from the company's Jul 2023 annual report; nothing newer is on file here.
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Chernett Jorey | 9.50% | 3.80M | 13G | Feb 13, 2026 |
| Sirenia Capital Management LP | 7.70% | 4.05M | 13G | May 15, 2026 |
| Woodline Partners LP | 7.00% | 3.65M | 13G | May 15, 2026 |
| Laura Natalia Monica Fonda | 5.01% | 1.93M | 13G | Oct 29, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 27, 2026 | Rajkumar V. Patilofficer: Chief Scientific Officer | Purchase | 3,363 | $1.49 | 20,030 |
| Jul 21, 2026 | Flavio Mantelliofficer: CHIEF MEDICAL OFFICER | Purchase | 20,000 | $1.40 | 20,000 |
| Jul 20, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 25,000 | $1.40 | 10,851,416 |
| Jul 21, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 22,500 | $1.45 | 10,873,916 |
| Jul 21, 2026 | Gary S. Jacobdirector, officer: CHIEF DEVELOPMENT OFFICER | Purchase | 3,500 | $1.40 | 112,420 |
| Jul 22, 2026 | Robert John Dempseydirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 15,000 | $1.54 | 15,000 |
| Jul 21, 2026 | John P. Brancacciodirector | Purchase | 5,000 | $1.48 | 35,201 |
House and Senate disclosures
Not reported.